Comparison · NCT01258049-99756bb7
ArTiMist vs Quinine: Late Clinical Failure
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ArTiMist vs Quinine: Late Clinical Failure. Trial comparisons, record NCT01258049-99756bb7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01258049-99756bb7
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0429 | 0.0147 | 0.119 | wilson | |
| Risk in group 2 | 0.0141 | 0.00249 | 0.0756 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0288 | -0.0389 | 0.105 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.04 | 0.324 | 28.6 | log | |
| Odds ratio, group 1 over group 2 | 3.13 | 0.318 | 30.9 | log | |
| Number needed to treat, for one more participant with the outcome on ArTiMist than on Quinine | 34.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ArTiMist | 3 | 70 | OG000 | |
| Group 2 | Quinine | 1 | 71 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Late Clinical Failure
- Description
* Signs of severe malaria on any day between Day 4 and Day 28 in the presence of parasitaemia, without previously meeting any of the criteria of early treatment failure~* Presence of parasitaemia and tympanic temperature ≥ 38.0°C (or history of fever), on any day between Day 4 and Day 28, without previously meeting any of the criteria of early treatment failure
- Time frame
- 28 days after the start of treatment
- Population
Source ClinicalTrials.gov
Trial
- Title
- Superiority of ArTiMist Versus Quinine in Children With Severe Malaria
- NCT number
- NCT01258049
- Phases
- PHASE3
- Conditions
- Plasmodium Falciparum Malaria
- Interventions
- Artemether Sublingual Spray, Quinine
- Lead sponsor
- Proto Pharma Ltd
- Results first posted
- 2014-02-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01258049?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01258049-99756bb7